PURPOSE: To determine the safety and efficacy of weekly high-dose oral calcitriol and docetaxel, given to patients with non-resectable, incurable pancreatic cancer. PATIENTS AND METHODS: Twenty-five patients were enrolled onto this phase II study. Patients were treated with oral calcitriol 0.5 microg/kg on day 1, followed by docetaxel 36 mg/m(2) IV on day 2, administered weekly for three consecutive weeks, followed by 1 week without treatment. Patients followed a low-calcium diet and increased their hydration. The primary end-point of the trial was time-to-progression. RESULTS: Three of 25 patients attained a partial response (12%, 95% CI 3 to 31) and seven (28%) achieved stable disease. Median time-to-progression was 15 weeks, and median overall survival was 24 weeks. Toxicities observed (hyperglycemia, fatigue) were mostly attributable to the docetaxel or its pre-treatment. CONCLUSIONS: This regimen of high-dose calcitriol with docetaxel may have activity in incurable pancreatic cancer, with a modest increase in TTP when compared to historical findings using single-agent docetaxel. However, results do not appear superior to those seen with gemcitabine, with or without erlotinib.
PURPOSE: To determine the safety and efficacy of weekly high-dose oral calcitriol and docetaxel, given to patients with non-resectable, incurable pancreatic cancer. PATIENTS AND METHODS: Twenty-five patients were enrolled onto this phase II study. Patients were treated with oral calcitriol 0.5 microg/kg on day 1, followed by docetaxel 36 mg/m(2) IV on day 2, administered weekly for three consecutive weeks, followed by 1 week without treatment. Patients followed a low-calcium diet and increased their hydration. The primary end-point of the trial was time-to-progression. RESULTS: Three of 25 patients attained a partial response (12%, 95% CI 3 to 31) and seven (28%) achieved stable disease. Median time-to-progression was 15 weeks, and median overall survival was 24 weeks. Toxicities observed (hyperglycemia, fatigue) were mostly attributable to the docetaxel or its pre-treatment. CONCLUSIONS: This regimen of high-dose calcitriol with docetaxel may have activity in incurable pancreatic cancer, with a modest increase in TTP when compared to historical findings using single-agent docetaxel. However, results do not appear superior to those seen with gemcitabine, with or without erlotinib.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Joan M Lappe; Dianne Travers-Gustafson; K Michael Davies; Robert R Recker; Robert P Heaney Journal: Am J Clin Nutr Date: 2007-06 Impact factor: 7.045
Authors: Kana Wu; Diane Feskanich; Charles S Fuchs; Walter C Willett; Bruce W Hollis; Edward L Giovannucci Journal: J Natl Cancer Inst Date: 2007-07-10 Impact factor: 13.506
Authors: Robert C Shepard; Donna E Levy; Jordan D Berlin; Keith Stuart; Jules E Harris; Victor Aviles; James P Thomas; Al Bowen Benson Journal: Oncology Date: 2004 Impact factor: 2.935
Authors: Brian M Wolpin; Kimmie Ng; Ying Bao; Peter Kraft; Meir J Stampfer; Dominique S Michaud; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Barbara B Cochrane; Jean Wactawski-Wende; Rowan T Chlebowski; Walter C Willett; JoAnn E Manson; Edward L Giovannucci; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-15 Impact factor: 4.254
Authors: Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Dennis B Bailey; Donald L Trump Journal: Cancer Chemother Pharmacol Date: 2010-03-21 Impact factor: 3.333
Authors: Michael Haas; Christoph Kern; Stephan Kruger; Marlies Michl; Dominik P Modest; Clemens Giessen; Christoph Schulz; Jobst C von Einem; Steffen Ormanns; Rüdiger P Laubender; Stefan Holdenrieder; Volker Heinemann; Stefan Boeck Journal: Tumour Biol Date: 2014-12-04
Authors: Michael D Arensman; Phillip Nguyen; Kathleen M Kershaw; Anna R Lay; Claire A Ostertag-Hill; Mara H Sherman; Michael Downes; Christopher Liddle; Ronald M Evans; David W Dawson Journal: Mol Cancer Res Date: 2015-07-29 Impact factor: 5.852